Cargando…

Prognostic value of early sustained ventricular arrhythmias in ST-segment elevation myocardial infarction treated by primary percutaneous coronary intervention: A substudy of VALIDATE-SWEDEHEART trial

BACKGROUND: Prognostic assessment of ventricular tachycardia (VT) or ventricular fibrillation (VF) in ST-segment elevation myocardial infarction (STEMI) is based mainly on distinguishing between early (<48 hours) and late arrhythmias, and does not take into account its time distribution with rega...

Descripción completa

Detalles Bibliográficos
Autores principales: Demidova, Marina M., Rylance, Rebecca, Koul, Sasha, Dworeck, Christian, James, Stefan, Aasa, Mikael, Hamid, Mehmet, Swahn, Eva, Hambraeus, Kristina, Danielewicz, Mikael, Linder, Rikard, Fröbert, Ole, Grimfjärd, Per, Stewart, Jason, Henareh, Loghman, Andersson, Jonas, Wagner, Henrik, Erlinge, David, Platonov, Pyotr G.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10041082/
https://www.ncbi.nlm.nih.gov/pubmed/36993916
http://dx.doi.org/10.1016/j.hroo.2022.12.008
_version_ 1784912628014907392
author Demidova, Marina M.
Rylance, Rebecca
Koul, Sasha
Dworeck, Christian
James, Stefan
Aasa, Mikael
Hamid, Mehmet
Swahn, Eva
Hambraeus, Kristina
Danielewicz, Mikael
Linder, Rikard
Fröbert, Ole
Grimfjärd, Per
Stewart, Jason
Henareh, Loghman
Andersson, Jonas
Wagner, Henrik
Erlinge, David
Platonov, Pyotr G.
author_facet Demidova, Marina M.
Rylance, Rebecca
Koul, Sasha
Dworeck, Christian
James, Stefan
Aasa, Mikael
Hamid, Mehmet
Swahn, Eva
Hambraeus, Kristina
Danielewicz, Mikael
Linder, Rikard
Fröbert, Ole
Grimfjärd, Per
Stewart, Jason
Henareh, Loghman
Andersson, Jonas
Wagner, Henrik
Erlinge, David
Platonov, Pyotr G.
author_sort Demidova, Marina M.
collection PubMed
description BACKGROUND: Prognostic assessment of ventricular tachycardia (VT) or ventricular fibrillation (VF) in ST-segment elevation myocardial infarction (STEMI) is based mainly on distinguishing between early (<48 hours) and late arrhythmias, and does not take into account its time distribution with regard to reperfusion, or type of arrhythmia. OBJECTIVE: We analyzed the prognostic value of early ventricular arrhythmias (VAs) in STEMI with regard to their type and timing. METHODS: The prespecified analysis of the multicenter prospective Bivalirudin versus Heparin in ST-Segment and Non-ST-Segment Elevation Myocardial Infarctionin Patients on Modern Antiplatelet Therapy in the Swedish Web System for Enhancement and Development of Evidence-based Care in Heart Disease evaluated according to Recommended Therapies Registry Trial included 2886 STEMI patients undergoing primary percutaneous coronary intervention (PCI). VA episodes were characterized regarding their type and timing. Survival status at 180 days was assessed through the population registry. RESULTS: Nonmonomorphic VT or VF was observed in 97 (3.4%) and monomorphic VT in 16 (0.5%) patients. Only 3 (2.7%) early VA episodes occurred after 24 hours from symptom onset. VA was associated with higher risk of death (hazard ratio 3.59; 95% confidence interval [CI] 2.01–6.42) after adjustment for age, sex, and STEMI localization. VA after PCI was associated with an increased mortality compared with VA before PCI (hazard ratio 6.68; 95% CI 2.90–15.41). Early VA was associated with in-hospital mortality (odds ratio 7.39; 95% CI 3.68–14.83) but not with long-term prognosis in patients discharged alive. The type of VA was not associated with mortality. CONCLUSION: VA after PCI was associated with an increased mortality compared with VA before PCI. Long-term prognosis did not differ between patients with monomorphic VT and nonmonomorphic VT or VF, but events were few. VA incidence during 24 to 48 hours of STEMI is negligibly low, thus precluding assessment of its prognostic importance.
format Online
Article
Text
id pubmed-10041082
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Elsevier
record_format MEDLINE/PubMed
spelling pubmed-100410822023-03-28 Prognostic value of early sustained ventricular arrhythmias in ST-segment elevation myocardial infarction treated by primary percutaneous coronary intervention: A substudy of VALIDATE-SWEDEHEART trial Demidova, Marina M. Rylance, Rebecca Koul, Sasha Dworeck, Christian James, Stefan Aasa, Mikael Hamid, Mehmet Swahn, Eva Hambraeus, Kristina Danielewicz, Mikael Linder, Rikard Fröbert, Ole Grimfjärd, Per Stewart, Jason Henareh, Loghman Andersson, Jonas Wagner, Henrik Erlinge, David Platonov, Pyotr G. Heart Rhythm O2 Clinical BACKGROUND: Prognostic assessment of ventricular tachycardia (VT) or ventricular fibrillation (VF) in ST-segment elevation myocardial infarction (STEMI) is based mainly on distinguishing between early (<48 hours) and late arrhythmias, and does not take into account its time distribution with regard to reperfusion, or type of arrhythmia. OBJECTIVE: We analyzed the prognostic value of early ventricular arrhythmias (VAs) in STEMI with regard to their type and timing. METHODS: The prespecified analysis of the multicenter prospective Bivalirudin versus Heparin in ST-Segment and Non-ST-Segment Elevation Myocardial Infarctionin Patients on Modern Antiplatelet Therapy in the Swedish Web System for Enhancement and Development of Evidence-based Care in Heart Disease evaluated according to Recommended Therapies Registry Trial included 2886 STEMI patients undergoing primary percutaneous coronary intervention (PCI). VA episodes were characterized regarding their type and timing. Survival status at 180 days was assessed through the population registry. RESULTS: Nonmonomorphic VT or VF was observed in 97 (3.4%) and monomorphic VT in 16 (0.5%) patients. Only 3 (2.7%) early VA episodes occurred after 24 hours from symptom onset. VA was associated with higher risk of death (hazard ratio 3.59; 95% confidence interval [CI] 2.01–6.42) after adjustment for age, sex, and STEMI localization. VA after PCI was associated with an increased mortality compared with VA before PCI (hazard ratio 6.68; 95% CI 2.90–15.41). Early VA was associated with in-hospital mortality (odds ratio 7.39; 95% CI 3.68–14.83) but not with long-term prognosis in patients discharged alive. The type of VA was not associated with mortality. CONCLUSION: VA after PCI was associated with an increased mortality compared with VA before PCI. Long-term prognosis did not differ between patients with monomorphic VT and nonmonomorphic VT or VF, but events were few. VA incidence during 24 to 48 hours of STEMI is negligibly low, thus precluding assessment of its prognostic importance. Elsevier 2022-12-22 /pmc/articles/PMC10041082/ /pubmed/36993916 http://dx.doi.org/10.1016/j.hroo.2022.12.008 Text en © 2022 Heart Rhythm Society. Published by Elsevier Inc. https://creativecommons.org/licenses/by/4.0/This is an open access article under the CC BY license (http://creativecommons.org/licenses/by/4.0/).
spellingShingle Clinical
Demidova, Marina M.
Rylance, Rebecca
Koul, Sasha
Dworeck, Christian
James, Stefan
Aasa, Mikael
Hamid, Mehmet
Swahn, Eva
Hambraeus, Kristina
Danielewicz, Mikael
Linder, Rikard
Fröbert, Ole
Grimfjärd, Per
Stewart, Jason
Henareh, Loghman
Andersson, Jonas
Wagner, Henrik
Erlinge, David
Platonov, Pyotr G.
Prognostic value of early sustained ventricular arrhythmias in ST-segment elevation myocardial infarction treated by primary percutaneous coronary intervention: A substudy of VALIDATE-SWEDEHEART trial
title Prognostic value of early sustained ventricular arrhythmias in ST-segment elevation myocardial infarction treated by primary percutaneous coronary intervention: A substudy of VALIDATE-SWEDEHEART trial
title_full Prognostic value of early sustained ventricular arrhythmias in ST-segment elevation myocardial infarction treated by primary percutaneous coronary intervention: A substudy of VALIDATE-SWEDEHEART trial
title_fullStr Prognostic value of early sustained ventricular arrhythmias in ST-segment elevation myocardial infarction treated by primary percutaneous coronary intervention: A substudy of VALIDATE-SWEDEHEART trial
title_full_unstemmed Prognostic value of early sustained ventricular arrhythmias in ST-segment elevation myocardial infarction treated by primary percutaneous coronary intervention: A substudy of VALIDATE-SWEDEHEART trial
title_short Prognostic value of early sustained ventricular arrhythmias in ST-segment elevation myocardial infarction treated by primary percutaneous coronary intervention: A substudy of VALIDATE-SWEDEHEART trial
title_sort prognostic value of early sustained ventricular arrhythmias in st-segment elevation myocardial infarction treated by primary percutaneous coronary intervention: a substudy of validate-swedeheart trial
topic Clinical
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10041082/
https://www.ncbi.nlm.nih.gov/pubmed/36993916
http://dx.doi.org/10.1016/j.hroo.2022.12.008
work_keys_str_mv AT demidovamarinam prognosticvalueofearlysustainedventriculararrhythmiasinstsegmentelevationmyocardialinfarctiontreatedbyprimarypercutaneouscoronaryinterventionasubstudyofvalidateswedehearttrial
AT rylancerebecca prognosticvalueofearlysustainedventriculararrhythmiasinstsegmentelevationmyocardialinfarctiontreatedbyprimarypercutaneouscoronaryinterventionasubstudyofvalidateswedehearttrial
AT koulsasha prognosticvalueofearlysustainedventriculararrhythmiasinstsegmentelevationmyocardialinfarctiontreatedbyprimarypercutaneouscoronaryinterventionasubstudyofvalidateswedehearttrial
AT dworeckchristian prognosticvalueofearlysustainedventriculararrhythmiasinstsegmentelevationmyocardialinfarctiontreatedbyprimarypercutaneouscoronaryinterventionasubstudyofvalidateswedehearttrial
AT jamesstefan prognosticvalueofearlysustainedventriculararrhythmiasinstsegmentelevationmyocardialinfarctiontreatedbyprimarypercutaneouscoronaryinterventionasubstudyofvalidateswedehearttrial
AT aasamikael prognosticvalueofearlysustainedventriculararrhythmiasinstsegmentelevationmyocardialinfarctiontreatedbyprimarypercutaneouscoronaryinterventionasubstudyofvalidateswedehearttrial
AT hamidmehmet prognosticvalueofearlysustainedventriculararrhythmiasinstsegmentelevationmyocardialinfarctiontreatedbyprimarypercutaneouscoronaryinterventionasubstudyofvalidateswedehearttrial
AT swahneva prognosticvalueofearlysustainedventriculararrhythmiasinstsegmentelevationmyocardialinfarctiontreatedbyprimarypercutaneouscoronaryinterventionasubstudyofvalidateswedehearttrial
AT hambraeuskristina prognosticvalueofearlysustainedventriculararrhythmiasinstsegmentelevationmyocardialinfarctiontreatedbyprimarypercutaneouscoronaryinterventionasubstudyofvalidateswedehearttrial
AT danielewiczmikael prognosticvalueofearlysustainedventriculararrhythmiasinstsegmentelevationmyocardialinfarctiontreatedbyprimarypercutaneouscoronaryinterventionasubstudyofvalidateswedehearttrial
AT linderrikard prognosticvalueofearlysustainedventriculararrhythmiasinstsegmentelevationmyocardialinfarctiontreatedbyprimarypercutaneouscoronaryinterventionasubstudyofvalidateswedehearttrial
AT frobertole prognosticvalueofearlysustainedventriculararrhythmiasinstsegmentelevationmyocardialinfarctiontreatedbyprimarypercutaneouscoronaryinterventionasubstudyofvalidateswedehearttrial
AT grimfjardper prognosticvalueofearlysustainedventriculararrhythmiasinstsegmentelevationmyocardialinfarctiontreatedbyprimarypercutaneouscoronaryinterventionasubstudyofvalidateswedehearttrial
AT stewartjason prognosticvalueofearlysustainedventriculararrhythmiasinstsegmentelevationmyocardialinfarctiontreatedbyprimarypercutaneouscoronaryinterventionasubstudyofvalidateswedehearttrial
AT henarehloghman prognosticvalueofearlysustainedventriculararrhythmiasinstsegmentelevationmyocardialinfarctiontreatedbyprimarypercutaneouscoronaryinterventionasubstudyofvalidateswedehearttrial
AT anderssonjonas prognosticvalueofearlysustainedventriculararrhythmiasinstsegmentelevationmyocardialinfarctiontreatedbyprimarypercutaneouscoronaryinterventionasubstudyofvalidateswedehearttrial
AT wagnerhenrik prognosticvalueofearlysustainedventriculararrhythmiasinstsegmentelevationmyocardialinfarctiontreatedbyprimarypercutaneouscoronaryinterventionasubstudyofvalidateswedehearttrial
AT erlingedavid prognosticvalueofearlysustainedventriculararrhythmiasinstsegmentelevationmyocardialinfarctiontreatedbyprimarypercutaneouscoronaryinterventionasubstudyofvalidateswedehearttrial
AT platonovpyotrg prognosticvalueofearlysustainedventriculararrhythmiasinstsegmentelevationmyocardialinfarctiontreatedbyprimarypercutaneouscoronaryinterventionasubstudyofvalidateswedehearttrial